Filing Scope and Business Context
The source text is a Form 10-K for Neuralstem, Inc., not Palisade Bio, Inc. It covers the fiscal year ended December 31, 2011, with selected unaudited quarterly data for fourth-quarter 2011. Neuralstem was a development-stage biotechnology company focused on human neural stem-cell therapies and small-molecule compounds for central nervous system diseases.
At year-end, all programs remained preclinical or clinical-stage. Key programs included a Phase I ALS stem-cell trial, a spinal-cord-injury program on FDA clinical hold, and the NSI-189 Phase Ia/Ib program for major depressive disorder.
Financial Performance and Position
| Metric | 2011 | 2010 | Change |
|---|---|---|---|
| Revenue | $390,625 | $733,438 | Down 47% |
| Operating expenses | $13,381,095 | $15,918,319 | Down 16% |
| Operating loss | $12,990,470 | $15,184,881 | Loss decreased 14% |
| Net loss | $12,518,527 | $18,387,300 | Loss decreased 32% |
| Basic and diluted loss per share | $0.26 | $0.42 | Improved |
| Net cash used in operating activities | $8,096,696 | $9,981,245 | Use decreased 19% |
| Cash and cash equivalents at year-end | $2,352,013 | $9,261,233 | Down 75% |
| Working capital | $590,385 | $7,093,237 | Down materially |
| Stockholders’ equity | $1,659,818 | $7,854,350 | Down 79% |
Revenue consisted of $390,625 recognized under a Department of Defense subcontract with Loma Linda University; the company generated no commercial product revenue. The filing does not provide a meaningful gross margin because the business was development-stage and revenue was contract-based. Net loss as a percentage of revenue was approximately 3,205%, compared with approximately 2,506% in 2010.
R&D expense was $7.4 million, down 20% primarily because of lower non-cash stock-based compensation and consulting costs. General and administrative expense was $5.8 million, down 12%, also principally due to lower stock-based compensation. Stock-based compensation totaled $3.3 million in 2011.
The filing discloses no material conventional debt balance at December 31, 2011. Total liabilities were $2.4 million, primarily accounts payable, accrued expenses, accrued bonus expense and no remaining warrant obligation. Lease commitments totaled $524,763.
Fourth-Quarter 2011 Results
| Metric | Q4 2011 |
|---|---|
| Revenue | $287,208 |
| Operating expenses | $2,849,240 |
| Net loss | $2,556,396 |
| Basic and diluted loss per share | $0.05 |
Fourth-quarter revenue represented approximately 74% of full-year revenue, reflecting recognition of the Loma Linda contract. The filing does not provide a separate Q4 cash-flow statement.
Material Changes Versus Prior Period
- Revenue declined $342,813 from 2010 because the prior-year revenue consisted of one-time federal grants totaling $733,438, while 2011 revenue came from the Loma Linda research contract.
- R&D and G&A expenses declined, but the company remained substantially unprofitable and dependent on external financing.
- Cash declined by $6.9 million during 2011. Operating cash use remained $8.1 million, while financing activities provided only $1.7 million, primarily from warrant exercises.
- The derivative warrant liability was eliminated by February 2011 as the remaining warrants were exercised or expired. This produced a $161,809 non-cash gain in 2011, compared with a $1.35 million non-cash loss in 2010.
- Shares outstanding increased to 48.7 million at December 31, 2011 from 46.9 million at December 31, 2010, with additional dilution possible from options, warrants and restricted awards.
Outlook, Liquidity, Risks and Unusual Items
Management estimated a monthly cash burn of approximately $1.0 million, expected to decline to approximately $700,000 in the second quarter of 2012 as accounts payable were brought current. Management believed available cash and expected income would fund current operations and clinical and preclinical work for at least 12 months from December 31, 2011, but stated that activities and personnel might need to be reduced.
After year-end, the company completed a February 2012 offering of 5.2 million shares and warrants for gross proceeds of $5.2 million and estimated net proceeds of $4.91 million. Management also disclosed a term sheet for an additional $2 million to $4 million private placement, although closing was not assured. The company was negotiating potential licensing agreements but had not completed those transactions.
- The ALS Phase I trial had treated 14 patients; FDA approval allowed cervical-region transplants for the final six patients after review of safety data from the first 12 patients.
- The chronic spinal-cord-injury IND remained on clinical hold, with no predictable approval date.
- The NSI-189 Phase Ia trial was completed in October 2011, and FDA approval for Phase Ib was received in December 2011. Management planned to begin the patient trial by the end of the first quarter of 2012.
- The company had accumulated losses of $98.5 million since inception and did not expect profitability in the next several years.
- Material risks included clinical-trial failure, regulatory delays, manufacturing dependence on third parties, intellectual-property disputes, additional financing needs and shareholder dilution.
- Neuralstem was involved in consolidated patent litigation with StemCells, Inc. and an arbitration involving a former placement agent seeking approximately $360,000. No liability was recorded for the arbitration claim.
- Employment agreements with the CEO and chief scientific officer included potential termination payments of up to $1 million each, plus accelerated vesting of equity awards.
Important Facts for Investors to Verify
- Confirm the issuer identity: the provided filing is for Neuralstem, Inc., while the request identifies Palisade Bio, Inc.
- Verify the status, terms and net proceeds of the February 2012 financing and whether the proposed $2 million to $4 million financing closed.
- Assess cash runway against the stated burn rate and the company’s continuing dependence on equity financing.
- Review subsequent clinical, FDA and trial-hold developments for ALS, chronic spinal-cord injury and NSI-189.
- Review the status and potential financial exposure of the StemCells patent litigation and placement-agent arbitration.
- Evaluate dilution from approximately 14.2 million outstanding warrants, 10.0 million options and other equity awards or reserved shares.